Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
-
Paragraph 0281; 0286; 0287
(2018/06/04)
Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors
The structure–activity and structure–kinetic relationships of a series of novel and selective ortho-aminoanilide inhibitors of histone deacetylases (HDACs) 1 and 2 are described. Different kinetic and thermodynamic selectivity profiles were obtained by va
Wagner, Florence F.,We?wer, Michel,Steinbacher, Stefan,Schomburg, Adrian,Reinemer, Peter,Gale, Jennifer P.,Campbell, Arthur J.,Fisher, Stewart L.,Zhao, Wen-Ning,Reis, Surya A.,Hennig, Krista M.,Thomas, Méryl,Müller, Peter,Jefson, Martin R.,Fass, Daniel M.,Haggarty, Stephen J.,Zhang, Yan-Ling,Holson, Edward B.
p. 4008 - 4015
(2016/08/23)
Glutamate receptor antagonists
The present invention is a compound of formula wherein X is an ethynediyl group, R1, R2and R3are as defined in the specification.
-
(2008/06/13)
More Articles about upstream products of 335255-05-5